Zosano Pharma Corp

Zosano Pharma — Investor Presentation (June 2015)

27 slides from Zosano Pharma's investor presentation, Jun 9, 2015

  1. Slide 1: Corporate Presentation

    Exhibit 99.1 Corporate Presentation June 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Thispresentationcontainsforward-lookingstatements.All statementsother than statementsof historicalfact containedin this presentation, including statementsregardingour commercialization,our researchand other developmentprograms,our ability to undertake certain activities an

  3. Slide 3: Zosano Pharma Drug Delivery System: Convenient and Easy-to-Use

    Zosano Pharma Drug Delivery System Convenient and Easy-to-Use : 2

  4. Slide 4: Zosano Pharma Drug Delivery System: Rapid Onset and High Bioavailability

    Zosano Pharma Drug Delivery System Rapid Onset and High Bioavailability Zosano approach provides rapid onset Hydrophilic drug formulation coated on tips of microneedles Microneedlesare 200-350micronslong– closeproximityto capillarybed Formulation quickly dissolved by interstitial fluid for short Tma

  5. Slide 5: Formulations Stable at Room Temperature

    Zosano Pharma Drug Delivery System Formulations Stable at Room Temperature Higher product stability, longer shelf life vs. injectables requiring refrigeration Dry, hydrophilic formulation of ZP-PTH more stable than Forteo liquid injectables Packaging purged with nitrogenno – moisture or oxygen ensur

  6. Slide 6: Broad ZP-Patch Compatibility Across Molecule Types

    Broad ZP-Patch Compatibility Across Molecule Types Rapid Onset Significant Criterion for Molecule Prioritization Technical Feasibility Prioritized for Screening Criteria With 30+ Compounds Development Preclinical Phase 1 Phase 2 Daily PTH Weekly PTH BNP Desmopressin Rapid onset provides Insulin ther

  7. Slide 7: Zosano Pharma (ZSAN) Investment Highlights

    Zosano Pharma (ZSAN) Investment Highlights Differentiated transdermal microneedle ZP-Patch delivery platform Capable of delivering small molecules, peptides/proteins and vaccines Fast onset with short Tmax: injection-comparable or better Convenient and easy-to-use: room temperature stable, portable

  8. Slide 8: Development Pipeline

    Development Pipeline Multiple Upcoming Milestones Preclinical Phase 1 Phase 2 Phase 3 Ph3 Daily ZP-PTH Start Osteoporosis Q1 16 Ph2 ZP-Glucagon P2Started Q1 2015 Data Severe hypoglycemia Q3 15 ZP-Triptan Ph1 Data Migraine Q4 15 Weekly GLP-1 Type 2 diabetes Undisclosed Multiple LEGEND: Upcoming Compl

  9. Slide 9: Overview of ZP-PTH Collaboration with Eli Lilly

    Overview of ZP-PTH Collaboration with Eli Lilly Attractive Partnership with PTH Market Leader Exclusive worldwide ZP-PTH license to Lilly Zosano responsible for Phase 3 clinical development, regulatory approvals and commercial readiness Lilly responsible for commercialization activities Attractive d

  10. Slide 10: Daily ZP-PTH Patch Program for Osteoporosis

    Daily ZP-PTH Patch Program for Osteoporosis Clinical Trial Design for Completed Phase 2 Study 6 month, five arm, multi-national BMD trial 165 post-menopausal women with low bone density 20 µg, 30 µg, 40 µg patches with Forteo and placebo as comparators Daily dosing self-administered by patients Prim

  11. Slide 11: Daily ZP-PTH Patch Program Phase 2 PK Profile

    Daily ZP-PTH Patch Program Phase – 2 PK Profile Pulsatile Delivery Critical for Building Bone Achieved dose proportionate and pulsatile pharmacokinetics Variability in patch doses comparable to Forteo injectable PK OVER TIME MEAN AUC BY DOSE HOURS 10

  12. Slide 12: Daily ZP-PTH Patch Program Phase 2 BMD Data

    Daily ZP-PTH Patch Program Phase – 2 BMD Data Higher Hip BMD Gains vs. Forteo HIP BMD SPINE BMD Increase in Increase in BMD (%) BMD (%) 4.970% 1.331% 3.470% 3.550% 2.960% 0.553% 0.138% 0.094% Placebo Placebo ZP-PTH ZP-PTH ZP-PTH FORTEO (0.330%) ZP-PTH ZP-PTH ZP-PTH FORTEO 20µg 30µg 40µg 20µg 20µg 30

  13. Slide 13: Daily ZP-PTH for Osteoporosis

    Daily ZP-PTH for Osteoporosis Planned Phase 3 Trial Design Single, non-inferiority Phase 3 trial comparing Daily ZP-PTH to Forteowith 505(b)(2) regulatory pathway Phase 3 is a larger and longer version of successful Phase 2 study Primary endpoint: Non-inferior change in spine BMD at 12 months 400 po

  14. Slide 14: ZP-Glucagon for Severe Hypoglycemia

    ZP-Glucagon for Severe Hypoglycemia Potential to Expand Highly Underserved Market Severe hypoglycemia is life-threatening, requiring emergency rescue Ease-of-use critical for third-party caregivers who may lack medical training Rapid onset important for fast recovery Underpenetrated market generates

  15. Slide 15: Treatment Time Critical for Emergency Rescue

    Treatment Time Critical for Emergency Rescue Current Products Not User-Friendly Currently Marketed Product Zosano Solution Complex, multi-step reconstitution, Press-and-Apply pre-loaded third party administered disposable system Significant prep time Fast, simple, no prep needed Unstable formulation

  16. Slide 16: Formulation Stability a Significant Competitive Advantage

    Formulation Stability a Significant Competitive Advantage Stability Demonstrated at 40° C over Six Months ZP-Glucagon Patch Stability 100 99 98 Formulation C 25C 97 Formulation C 40C Formulation D 25C 96 Formulation D 40C 95 0 1 2 3 4 5 6 7 Months 15

  17. Slide 17: ZP-Glucagon Phase 1 PK Data vs. Injection

    ZP-GlucagonPhase – 1 PK Data vs. Injection Short Tmax, High Bioavailability, and Low Variability Across Doses 20 subjects tested in five-way crossover study 16

  18. Slide 18: ZP-Glucagon Phase 1 Glucose Data vs. Injection

    ZP-GlucagonPhase – 1 Glucose Data vs. Injection PD for All Patch Doses Comparable to Injection Patch C, upper arm PatchC, forearm Patch C, abdomen Patch D,abdomen IM glucagon injection 17

  19. Slide 19: ZP-Glucagon for Severe Hypoglycemia: Next Steps

    ZP-Glucagon for Severe Hypoglycemia Next Steps Launch Gen 1 product using reusable applicator Phase 1 completed Q1 2014; received FDA feedback regarding development plan H2 2014 Phase 2 trial to compare patch vs. injection in diabetic patients with induction of hypoglycemia (16 patient crossover) co

  20. Slide 20: ZP-Triptan for Migraine

    ZP-Triptan for Migraine Highly Suited for Acute Condition Requiring Immediate Relief Potential best-in-class rapid onset: Tmax = 9 minutes Comparable or better onset of action than existing triptans/injectables Self-administration provides significant advantage vs. injectables Large, growing market

  21. Slide 21: ZP-Triptan for Migraine: High Bioavailability with Rapid Onset

    ZP-Triptan for Migraine Demonstrated High Bioavailability with Rapid Onset 1,400 1,200 IV Patch 1,000 800 600 400 200 0 0 30 60 90 120 150 180 Time, min AUC Abs BA % Route Dose (mg/kg) Tmax (min) Cmax (ng/mL) (ng*h/mL) (dosenorm) 1 ZP-Triptan 1.81 9 296 ±106 587 ±256 100 IV 1.26 1 203 ±27 1,103± 92

  22. Slide 22: Rapid Onset Associated with Pain Relief

    Rapid Onset Associated with Pain Relief ZP-Triptan With Potential Best-in-Class Onset of Action Nasal / Oral Oral Patch Subcutaneous ZP-Triptan (4) Melt(1) Tablets(2) Zecuity Injection(3) Tmax (Ave)(5) (H:MM) Pain Relief To be 2 hours (6) 63% 57% 53% 75% (Ave) evaluated Products Included: (1) Nasal:

  23. Slide 23: ZP-Triptan for Migraine: Next Steps

    ZP-Triptan for Migraine Next Steps Launch product using current applicator and patch Phase 1 data expected in Q4 2015 Single/multi dose crossover study versus SC/IM injection Multiple patch doses with zolmitriptan compared to one subcutaneous injection of sumatriptan in healthy volunteers Phase 2 tr

  24. Slide 24: Once-Weekly GLP-1 Patch for Type 2 Diabetes

    Once-Weekly GLP-1 Patch for Type 2 Diabetes Exclusive Partnership with Novo Nordisk in Blockbuster Market Zosanogrants Novo Nordisk exclusive rights to develop patch formulations of Novo GLP-1 analogs 1 Large, growing market: 2014 U.S. GLP-1 >sales $3 billion USD 2 Novo/Victoza 2014 TRx market share

  25. Slide 25: ZP-Patch Intellectual Property

    ZP-Patch Intellectual Property Patent Protection Until 2027 Issued Patents (owned & licensed) = 22 US, 12 EU, 13 JP Transdermal & PTH Formulation/ Coating/PK/PD 7 US, 3 EU, 5 JP Micro Projection Mfg & ZP Design & Packaging Technology Anchoring to 3 US, 1 JP Platform Skin 4 US, 2 EU, 2 JP Patch Appli

  26. Slide 26: Zosano Pharma (ZSAN) Investment Highlights

    Zosano Pharma (ZSAN) Investment Highlights Differentiated transdermal microneedle ZP-Patch delivery platform Capable of delivering small molecules, peptides/proteins and vaccines Fast onset with short Tmax: injection-comparable or better Convenient and easy-to-use: room temperature stable, portable

  27. Slide 27: Corporate Presentation

    Corporate Presentation June 2015

Zosano Pharma — Investor Presentation (June 2015) on 6ix